Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Folker Westphal

Showing results (51-60 of 61) with videos related to

Pageof 7
Sort By:
Archives of Toxicology|April 7, 2020
Toxicokinetics and toxicodynamics of the fentanyl homologs cyclopropanoyl-1-benzyl-4´-fluoro-4-anilinopiperidine and furanoyl-1-benzyl-4-anilinopiperidineTanja M Gampfer, Lea Wagmann, Yu Mi Park, et al.
Journal of Pharmaceutical and Biomedical Analysis|May 1, 2024
Metabolism and cytotoxicity studies of the two hallucinogens 1cP-LSD and 4-AcO-DET in human liver and zebrafish larvae models using LC-HRMS/MS and a high-content screening assayTanja M Gampfer, Victoria Schütz, Philip Schippers, et al.
Drug Testing and Analysis|July 4, 2017
Structural characterization and pharmacological evaluation of the new synthetic cannabinoid CUMYL-PEGACLONEVerena Angerer, Lukas Mogler, Jan-Patrick Steitz, et al.
Drug Testing and Analysis|December 21, 2022
Pharmacology, prevalence in Germany, and analytical data of cyclobutylmethyl- and norbornylmethyl-type synthetic cannabinoid receptor agonistsBenedikt Pulver, Jan Riedel, Torsten Schönberger, et al.
Archives of Toxicology|May 20, 2026
Global emergence and γ-aminobutyric acid type A (GABA<sub>A</sub>) receptor activity of the new designer benzodiazepine ethylbromazolamCaitlyn Norman, Dean Acreman, Meera Bissram, et al.
Drug Testing and Analysis|March 18, 2020
Return of the lysergamides. Part VI: Analytical and behavioural characterization of 1-cyclopropanoyl-d-lysergic acid diethylamide (1CP-LSD)Simon D Brandt, Pierce V Kavanagh, Folker Westphal, et al.
Drug Testing and Analysis|April 20, 2018
Synthesis, analytical characterization, and monoamine transporter activity of the new psychoactive substance 4-methylphenmetrazine (4-MPM), with differentiation from its ortho- and meta- positional isomersGavin McLaughlin, Michael H Baumann, Pierce V Kavanagh, et al.
Drug Testing and Analysis|March 26, 2022
Structure elucidation of the novel synthetic cannabinoid Cumyl-Tosyl-Indazole-3-Carboxamide (Cumyl-TsINACA) found in illicit products in GermanyBenedikt Pulver, Torsten Schönberger, Diana Weigel, et al.
Drug Testing and Analysis|May 6, 2022
The ADEBAR project: European and international provision of analytical data from structure elucidation and analytical characterization of NPSBenedikt Pulver, Svenja Fischmann, Folker Westphal, et al.
Drug Testing and Analysis|June 7, 2016
Return of the lysergamides. Part II: Analytical and behavioural characterization of N<sup>6</sup> -allyl-6-norlysergic acid diethylamide (AL-LAD) and (2'S,4'S)-lysergic acid 2,4-dimethylazetidide (LSZ)Simon D Brandt, Pierce V Kavanagh, Folker Westphal, et al.
Pageof 7

Showing results (51-60 of 61) with videos related to

Sort By:
Pageof 7
Archives of Toxicology|April 7, 2020
Toxicokinetics and toxicodynamics of the fentanyl homologs cyclopropanoyl-1-benzyl-4´-fluoro-4-anilinopiperidine and furanoyl-1-benzyl-4-anilinopiperidineTanja M Gampfer, Lea Wagmann, Yu Mi Park, et al.
Journal of Pharmaceutical and Biomedical Analysis|May 1, 2024
Metabolism and cytotoxicity studies of the two hallucinogens 1cP-LSD and 4-AcO-DET in human liver and zebrafish larvae models using LC-HRMS/MS and a high-content screening assayTanja M Gampfer, Victoria Schütz, Philip Schippers, et al.
Drug Testing and Analysis|July 4, 2017
Structural characterization and pharmacological evaluation of the new synthetic cannabinoid CUMYL-PEGACLONEVerena Angerer, Lukas Mogler, Jan-Patrick Steitz, et al.
Drug Testing and Analysis|December 21, 2022
Pharmacology, prevalence in Germany, and analytical data of cyclobutylmethyl- and norbornylmethyl-type synthetic cannabinoid receptor agonistsBenedikt Pulver, Jan Riedel, Torsten Schönberger, et al.
Archives of Toxicology|May 20, 2026
Global emergence and γ-aminobutyric acid type A (GABA<sub>A</sub>) receptor activity of the new designer benzodiazepine ethylbromazolamCaitlyn Norman, Dean Acreman, Meera Bissram, et al.
Drug Testing and Analysis|March 18, 2020
Return of the lysergamides. Part VI: Analytical and behavioural characterization of 1-cyclopropanoyl-d-lysergic acid diethylamide (1CP-LSD)Simon D Brandt, Pierce V Kavanagh, Folker Westphal, et al.
Drug Testing and Analysis|April 20, 2018
Synthesis, analytical characterization, and monoamine transporter activity of the new psychoactive substance 4-methylphenmetrazine (4-MPM), with differentiation from its ortho- and meta- positional isomersGavin McLaughlin, Michael H Baumann, Pierce V Kavanagh, et al.
Drug Testing and Analysis|March 26, 2022
Structure elucidation of the novel synthetic cannabinoid Cumyl-Tosyl-Indazole-3-Carboxamide (Cumyl-TsINACA) found in illicit products in GermanyBenedikt Pulver, Torsten Schönberger, Diana Weigel, et al.
Drug Testing and Analysis|May 6, 2022
The ADEBAR project: European and international provision of analytical data from structure elucidation and analytical characterization of NPSBenedikt Pulver, Svenja Fischmann, Folker Westphal, et al.
Drug Testing and Analysis|June 7, 2016
Return of the lysergamides. Part II: Analytical and behavioural characterization of N<sup>6</sup> -allyl-6-norlysergic acid diethylamide (AL-LAD) and (2'S,4'S)-lysergic acid 2,4-dimethylazetidide (LSZ)Simon D Brandt, Pierce V Kavanagh, Folker Westphal, et al.
Pageof 7